European Society of Toxicologic Pathology (Pathology 2.0 Molecular Pathology Special Interest Group): Review of In Situ Hybridization Techniques for Drug Research and Development
Toxicologic Pathology · 2023-04 · 51 (3) · 92-111
DOI: 10.1177/01926233231178282 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Toxicologic Pathology, online erschienen am 14.07.2023. Verfasst von Josep M Monné Rodríguez und 11 weiteren Autor:innen. Beteiligte Einrichtung: F. Hoffmann-La Roche Ltd, Basel, Switzerland. Hauptthemen laut MEDLINE: Pathology, Molecular, Public Opinion. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 193 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In situ hybridization (ISH) is used for the localization of specific nucleic acid sequences in cells or tissues by complementary binding of a nucleotide probe to a specific target nucleic acid sequence. In the last years, the specificity and sensitivity of ISH assays were improved by innovative techniques like synthetic nucleic acids and tandem oligonucleotide probes combined with signal amplification methods like branched DNA, hybridization chain reaction and tyramide signal amplification. These improvements increased the application spectrum for ISH on formalin-fixed paraffin-embedded tissues. ISH is a powerful tool to investigate DNA, mRNA transcripts, regulatory noncoding RNA, and therapeutic oligonucleotides. ISH can be used to obtain spatial information of a cell type, subcellular localization, or expression levels of targets. Since immunohistochemistry and ISH share similar workflows, their combination can address simultaneous transcriptomics and proteomics questions. The goal of this review paper is to revisit the current state of the scientific approaches in ISH and its application in drug research and development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- F. Hoffmann-La Roche Ltd, Basel, Switzerland.
- University of Zurich, Zurich, Switzerland.
- Janssen Research & Development, Beerse, Belgium.
- AnaPath Services GmbH, Liestal, Switzerland.
- StageBio, Freiburg, Germany.
- Excilone Services, Jouy-en-Josas, France.
ORCID-Profile: Anna-Lena Frisk, Chandrassegar Saravanan, Enrico Vezzali, Dirk Schaudien
Zitieren
APA
Monné Rodríguez, J. M., Frisk, A. L., Kreutzer, R., Lemarchand, T., Lezmi, S., Saravanan, C., Stierstorfer, B., Thuilliez, C., Vezzali, E., Wieczorek, G., Yun, S. W., & Schaudien, D. (2023). European Society of Toxicologic Pathology (Pathology 2.0 Molecular Pathology Special Interest Group): Review of In Situ Hybridization Techniques for Drug Research and Development. Toxicologic Pathology, 51(3), 92-111. https://doi.org/10.1177/01926233231178282
Vancouver
Monné Rodríguez JM, Frisk AL, Kreutzer R, Lemarchand T, Lezmi S, Saravanan C, et al. European Society of Toxicologic Pathology (Pathology 2.0 Molecular Pathology Special Interest Group): Review of In Situ Hybridization Techniques for Drug Research and Development. Toxicologic Pathology. 2023;51(3):92-111. doi:10.1177/01926233231178282
BibTeX
@article{MonnRodrguez2023,
author = {Monné Rodríguez, Josep M and Frisk, Anna-Lena and Kreutzer, Robert and Lemarchand, Thomas and Lezmi, Stephane and Saravanan, Chandrassegar and Stierstorfer, Birgit and Thuilliez, Céline and Vezzali, Enrico and Wieczorek, Grazyna and Yun, Seong-Wook and Schaudien, Dirk},
title = {European Society of Toxicologic Pathology (Pathology 2.0 Molecular Pathology Special Interest Group): Review of In Situ Hybridization Techniques for Drug Research and Development},
journal = {Toxicologic Pathology},
year = {2023},
volume = {51},
number = {3},
pages = {92--111},
doi = {10.1177/01926233231178282}
}
EUVIMED